Chimney Trial : study protocol for a randomized controlled trial by Mäkäräinen-Uhlbäck, Elisa et al.
STUDY PROTOCOL Open Access
Chimney Trial: study protocol for a
randomized controlled trial
Elisa Mäkäräinen-Uhlbäck1* , Heikki Wiik1, Jyrki Kössi2, Maziar Nikberg3, Pasi Ohtonen1 and Tero Rautio1
Abstract
Background: Parastomal hernias (PSHs) are common, troubling the lives of people with permanent colostomy. In
previous studies, retromuscular keyhole mesh placement has been the most-used technique for PSH prevention
but results have been controversial. Additionally, surgical treatment of PSHs is associated with a high rate of
complications and recurrences. Therefore, it is crucial to find the most effective way to prevent PSHs in the first
place without an increased risk of complications. Due to a lack of adequate research, there is no clear evidence or
recommendations on which mesh or technique is best to prevent PSHs.
Methods/design: The Chimney Trial is a Nordic, prospective, randomized controlled, multicenter trial designed to
compare the feasibility and the potential benefits of specifically designed, intra-abdominal onlay mesh (DynaMesh®-
Parastomal, FEG Textiltechnik GmbH, Aachen, Germany) against controls with permanent colostomy without mesh.
The primary outcome of the Chimney Trial is the incidence of a PSH detected by a computerized tomography (CT)
scan at 12-month follow-up. Secondary outcomes are the rate of clinically detected PSHs, surgical-site infection as
defined by the Centers for Disease Control and Prevention (CDC), complications as defined by the Clavien-Dindo
classification, the reoperation rate, operative time, length of stay, quality of life as measured by the RAND-36 survey
and colostomy impact score, and both direct and indirect costs. For each group, 102 patients were enrolled at
attending hospitals and randomized at a ratio of 1:1 by browser-based software to receive a preventive mesh or a
conventional colostomy without a mesh. Patients will be followed for 1 month and at 1, 3, and 5 years after the
operation for long-term results and complications.
Discussion: The Chimney Trial aims to provide level-I evidence on PSH prevention.
Trial registration: ClinicalTrials.gov, ID: NCT03799939. Registered on 10 January 2019
Keywords: Parastomal hernia prevention, Abdominoperineal resection, Rectal cancer treatment
Introduction
Background and rationale
Abdominoperineal resection (APR) with permanent end-
colostomy formation was introduced in the late twenti-
eth century as a surgical method to treat distal rectal
cancer in order to decrease the previously high incidence
of local recurrence [1, 2]. Despite the rising trend of sav-
ing sphincter function, APR still remains the primary
operation of choice for patients with low rectal cancer
[3]. Even more, the low Hartmann’s procedure with per-
manent colostomy is increasingly performed in older
and frailer patients who are not suitable for an anasto-
moses [4].
The reported incidence of parastomal hernias (PSHs)
with permanent end colostomy rises to 81% after long-
term follow-up [5]. Due to increased use of minimally
invasive rectal cancer surgery and better survival, an
increased incidence of PSHs might be expected [6, 7].
Many PSHs are asymptomatic, and clinical examina-
tions can reveal only some of them compared with
computed tomography (CT) scans [7, 8]. Most PSHs
are diagnosed within 2 years after the construction of
the stoma, but their incidence increases after longer
follow-up [5, 9, 10].
The results of PSH repair are still unsatisfactory due
to a high rate of complications [11]. Therefore, the initial
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focus should be on prevention, which is recommended
in guidelines by the European Hernia Society [11].
Several randomized control trials (RCTs) and meta-
analyses have shown positive results for synthetic
meshes utilized as prophylaxis with various techniques
and meshes [5, 6, 12–19]. Trials have demonstrated a
lower incidence of PSHs without a higher risk of compli-
cations. However, despite the use of a prophylactic
mesh, the incidence of PSHs has been surprisingly high.
Clinically detected hernias are present in up to 10.6–
16.4% of patients with a parastomal mesh, and the inci-
dence of radiologically detected hernias is 32.4–36.6%
on recent meta-analyses [18, 20]. Additionally, a recently
published RCT [21] reported similar rates of radiologic-
ally detected PSHs at 1 year after open APR in patients
with (32%) and without (34%) a prophylactic retromus-
cular sublay mesh.
Polyvinylidene difluoride mesh (PVDF, DynaMesh®-
IPST, FEG Textiltechnik GmbH, Aachen, Germany) is a
synthetic mesh with a 4-cm-long, central, seamless tube
(chimney) designed to repair and prevent PSHs. There
are three case series [22–24] published on its use as a
prophylactic mesh. In 2008, Berger et al. [22] found no
clinically detectable hernias by CT scan at 1-year follow-
up. In another trial, [23] the incidence of PSHs was
clinically found 3.2% and in CT scans 6.4% at the 1-year
follow-up in a case series of 31 patients. The prophylac-
tic method was safe with no unexpected complications.
No RCTs have been published so far. The design of the
mesh with a central tube forming a stocking-like lining
around the bowel may be crucial for PSH prevention
[22] and blocking stomal-orifice enlargement occurring
with keyhole techniques [13].
Objectives
The objective of this study is to compare prospectively
in a randomized setting the feasibility and potential
benefits of specifically designed, intra-abdominal, onlay
mesh (DynaMesh®-IPST, FEG Textiltechnik GmbH,
Aachen, Germany) with controls having conventional
colostomy without mesh in patients operated on with
minimally invasive surgery.
There are very few studies on specially designed PVDF
mesh in PSH prophylaxis, but the concept of tight, tube-
fashioned mesh surrounding the bowel and stomal ori-
fice might be beneficial. We hypothesize that the high
rate of PSHs seen in previous trials with retromuscular
keyhole mesh is due to the central hole, and the draw-
back may be avoidable with the use of specially designed
PVDF mesh.
Trial design
The Chimney Trial is designed as a prospective, ran-
domized, controlled, multicenter, single-blinded study of
patients who had undergone either mini-invasive laparo-
scopic and robotic-assisted APR or low Hartmann’s pro-
cedure for rectal adenocarcinoma. The trial is
independent from any kind of industrial sponsorship.
Previous research on PVDF mesh used for PSH pre-
vention is scarce. We conduct and evaluate the compli-
cations and adverse events of PVDF mesh for safety
reasons for 30 patients who have completed 30 days’
follow-up in a group with the mesh and another group
with a conventional colostomy without a mesh. If there
are 10% or more serious complications defined by
Clavien-Dindo classification 3B in either group, the trial
will be regarded as unethical and will be terminated. For
the same safety reasons, there will be further analyses on
the effectiveness and complications when 30 patients in
both groups have reached the 1-year follow-up. If the
PSH rate is increased by more than 35% in the control
group compared with the PVDF-mesh group or there
are 10% or more complications defined by Clavien-
Dindo classification 3B in either group compared with
the other group, the trial will be terminated as unethical
to continue. In case of terminating the trial prematurely,




This study is a multicenter study involving several Nor-
dic hospitals. Hospitals currently participating in this
study are Oulu University Hospital, Helsinki University
Hospital, Turku University Hospital, Tampere University
Hospital, Jyväskylä Central Hospital, and Seinäjoki
Central Hospital in Finland and Västmanlands Hospital
Västerås in Sweden. It is expected that hospitals from
other Nordic countries, such as Norway and Denmark,
will join the trial later.
Oulu University Hospital and Seinäjoki Central
Hospital began recruitment in February 2019 with other
hospitals soon to following.
Eligibility criteria
All patients who fulfill the inclusion criteria without
meeting any of the exclusion criteria are considered to
participate in the trial at any of the hospitals during the
study period (Fig. 1). Patients are enrolled in the study
in the outpatient department at a visit prior to surgery.
All patients who undergo APR or Hartmann’s procedure
for rectal adenocarcinoma during the study period in
each attending hospital are recorded without identifica-
tion details for later analysis of selection biases.
If a patient refuses to attend the trial, they are treated
according to routine practice.
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Fig. 1 Flow chart
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Inclusion criteria
 APR or low Hartmann’s procedure for rectal cancer
with curative intent and permanent end colostomy,
either by laparoscopic technique or robotic-assisted
APR
 18 years of age or older
 Patient has a life expectancy of at least 12 months
 Patient signs the informed consent and agrees to
attend all study visits
Exclusion criteria
 APR or Hartmann’s resection by laparotomy or
conversion to laparotomy
 Complications requiring laparotomy during
postoperative treatment on the surgical ward
 Patient with a comorbid illness or condition that
would preclude surgical treatment (American
Society of Anesthesiologists (ASA) 4–5)
 Patients with concurrent or previous malignant
tumors within 5 years before study enrollment
 Patients with grade-T4b tumors that impose a
multi-organ resection
 Rectal malignancy other than adenocarcinoma
 Patients undergoing emergency procedures
 Planned rectal surgery along with major
concomitant procedures (e.g., hepatectomies, other
intestinal resections)
 Metastatic disease with no possibility of curative
surgery
 Pregnancy or suspected pregnancy
 Patients living geographically distant and/or
unwilling to return for follow-ups or comply with all
study requirements
 Active abdominal infection at the time of surgery
 Previous surgery at the colostomy site
 Language barrier or other reasons why informed
consent is not possible
Interventions
Perioperative care includes the assessment and
optimization of medical risk factors, thromboprophylaxis
with low-molecular-weight heparin and elastic antiem-
bolic stockings, standard anesthesia and the avoidance of
hypothermia. Antibiotic prophylaxis and mechanical
bowel preparation are accomplished according to the
hospital protocol. Postoperative treatment on the surgi-
cal ward is accomplished according to standard en-
hanced recovery after surgery (ERAS) protocols.
Surgical technique
PVDF mesh (DynaMesh®-IPST, FEG Textiltechnik GmbH,
Aachen, Germany) is placed on the intraperitoneal surface
as described by Berger et al. [22], Conde-Muino et al. [23]
and Köhler et al. [24]. The bowel forming the colostomy is
closed with a linear-stapling device. The trephine is cre-
ated by excision of the skin at the site previously marked
by a trained ostomy nurse. Subcutaneous tissue is not ex-
cised. A cross-shaped incision is made to the anterior rec-
tus sheath. The rectus abdominis muscle is split in the
direction of the fibers, and the posterior rectus sheath is
opened longitudinally. A 15 × 15-cm mesh with a tube
length of 4 cm and a width of 2 cm is used (Fig. 2). The
tube is stretched using the surgeon’s fingers to match the
diameter of the bowel (Fig. 3). The bowel is brought
through the orifice and then through the saline lubricated
tube in the PVDF mesh (Fig. 4). The mesh is translocated
into the intra-abdominal space with the funnel oriented
dorsally and fixed in the intraperitoneal onlay position by
absorbable tackers (Securestrap™, Ethicon) using the
double-crown technique as described and pictured previ-
ously by Köhler et al. [24] (Fig. 5) The corners of the mesh
are fixed first, then the tackers are attached every 2 cm on
the outer row. The inner row is fixed at 12, 3, 6, and 9
o’clock positions. The stoma is fixed and everted with ab-
sorbable monofilament sutures to the skin just above the
skin level. A catalog of the operative technique will be sent
to all participating surgeons to standardize the procedure.
In the control group, the colostomy is formed by the
identical method as described above. The only difference
is that there will be no mesh.
Outcomes
The primary endpoint of this study is the incidence of
PSHs, either symptomatic or asymptomatic, detected by
a CT scan during the 12 months’ post-surgery follow-up.
A CT scan with the Valsalva maneuver being performed
is performed at the 1-year and 3-year follow-up after
rectal adenocarcinoma operation as a part of routine
follow-up protocol and to detect the incidence of
Fig. 2 The polyvinylidene difluoride (PVDF) mesh (DynaMesh®-IPST,
FEG Textiltechnik GmbH, Aachen, Germany) with the 4-cm
long funnel
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radiological PSHs. All patients are also assessed at each
follow-up point (Table 1) by an experienced surgeon to
detect clinical PSH or complication of stoma as second-
ary outcome. There will be clinical evaluation without
CT scan to detect any clinical PSH as long-term follow-
up at 5 years after surgery.
All CT scans are analyzed by two independent radi-
ologists. Measurements are recorded of fascial defect
at stoma, the size of any possible PSH sac and fascial
defect of a hernia, the content of the hernial sac, the
location of the stoma and other hernias. The hernias
will be graded according to the European Hernia So-
ciety criteria [25].
Primary outcome
 PSH, either symptomatic or asymptomatic, detected
by CT scan during 12 months’ follow-up
Secondary outcomes
 Incidence of CT-detected PSH during 3-year follow-
up
 Incidence of clinically detected PSH during 1-, 3-,
and 5-year follow-ups
 PSH-operation-free survival at 3 and 5 years
 Surgical-site infection (SSI) rate
 Clavien-Dindo grade I–V complications at 30 days
postoperatively





 Length of stay (LOS) in days
 Quality of life (RAND-36, colostomy impact score)
 Medico-economic sub-study including direct costs
at hospital and indirect costs caused by sick leave
 Radiological sub-study including definition of
abdominal wall measurements and location of stoma
Radiological sub-study
 Subcutaneous abdominal fat in centimeters on the
contra-lateral side of the stoma
 Distance of the medial part of the stoma to midline
(umbilicus as the midline definition)
 Area of the stoma aperture (2 cm width × height/2)
The SSI is defined and recorded per the Centers
for Disease Control and Prevention (CDC) SSI defin-
ition [25].
Clavien-Dindo classification is utilized for complica-
tions. All related costs are analyzed in detail. The direct
costs, including the meshes, resources and stay at the
hospital, are monitored, and the indirect costs from
losses of productivity are recorded.
Pre-intervention data
 Age
Fig. 3 The funnel-shaped tube is stretched with fingers to match
the diameter of the bowel
Fig. 4 The bowel is brought through the funnel oriented dorsally
Fig. 5 The polyvinylidene difluoride (PVDF) mesh is attached to the
abdominal wall using absorbable tackers




 Other illnesses and medications
 Smoking history
 Previous hernias, either symptomatic or
asymptomatic
 Neoadjuvant treatment
 Preoperative hemoglobin and carcinoembryonic
antigen (CEA)
 Quality of life defined by the RAND-36





 Resources used during the operation
 Total blood loss
Post-intervention data
 Length of postoperative ileus (POI) measured in
days and defined by air in the stoma
 Re-operation rate
 Complications as defined by Clavien-Dindo
classification
 Incidence of SSI as defined by the CDC
 Incidence of either clinically or radiologically
detected PSHs
 Quality of life at each follow-up
 Problems and complications with stoma
 Tumor–nodes–metastases (TNM) score
 Hemoglobin and CEA at each control
 Oncological adjuvant treatment given
All exceptions to the protocol are recorded and ex-
plained in detail at each time point.
Sample size
To calculate a sample size needed to compare the two
groups, we estimated a 6.4% rate of PSH and 34% PSH
on a CT scan for the PVDF-mesh group and control
group during 12 months’ follow-up [21, 23]. Assuming
α = 0.05 and power = 90%, we would need 51 patients
per group. Furthermore, assuming a 5-year drop-out rate
of 50%, 102 patients per group are needed to reach sta-
tistically significant results also during long-term follow-
up.
All analyses will be performed by, or under the guid-
ance of, professional statisticians and following the Con-
solidated Standards of Reporting Trials (CONSORT)
guidelines [26].
Recruitment
All patients who will undergo laparoscopic or robotic-
assisted APR or low Hartmann’s procedure for rectal
adenocarcinoma at each study site are considered for the
trial at the time of their visit to the outpatient depart-
ment prior to surgery. After receiving the proper infor-
mation on the possible advantages and disadvantages of
the intervention, and voluntarily signing an informed
consent form, the subject is enrolled in the Chimney
Trial. Participating investigators are qualified colorectal
or general surgeons experienced in the surgical manage-
ment of patients with colorectal adenocarcinoma and
either laparoscopic or robotic-assisted APR or low Hart-
mann’s procedure. Each hospital’s contribution to the
study is limited to no less than 20 cases. The enrollment
will last for approximately 2 to 3 years in attending
hospitals.
Table 1 Participant timeline











Demographics and medical history X
QoL (RAND-36) X X X X X
QoL (colostomy impact score) X X X X
Procedure details X
CT scan findings X X
Protocol deviation Xa Xa Xa Xa Xa Xa Xa Xa
Complications Xa Xa Xa Xa Xa Xa Xa
Study closure form Xb
Legend: CT computed tomography, QoL quality of life
aComplete if applicable
bComplete when lost to follow-up, consent withdrawal or subject has completed all study-related visits
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Methods
Allocation
All analyses will be performed by or under the guidance
of professional statisticians and following the CONSORT
guidelines [26].
Patients are randomly allocated to the study group ac-
cording to a computer-generated list, compiled by a bio-
statistician who is not involved in the clinical care of
trial patients. The randomization is performed in blocks,
where the block size varies randomly between two, four,
and six patients. A separate randomization list is created
for each center. The software designed for the study is
used to randomize the patients. After confirmation of
patients’ eligibility and their willingness to participate,
the randomization is completed at the outpatient visit
prior to surgery and the patients are kept blinded to
study technique.
Blinding
Patients are blinded to the randomization group during
their primary stay at the hospital. For safety reasons,
their group designation is stated in the patients’ medical
files for direct access in case of complications. The pa-
tient has direct access to their medical records after
hospitalization and, therefore, the blinding is not pos-
sible to maintain. Patients are assigned at the control
visits by a surgeon not involved in the study and without
accessing the randomization group. The independent ra-
diologists analyze the CT scan without access to the
randomization group information.
Data collection, management and analysis
A dedicated electronic database and randomization soft-
ware program is used to host the clinical trial data for
this study. All electronic case report forms (eCRFs) are
handled with a special trial ID. Access to the database is
limited to the main investigators. All data requested on
the eCRFs will be recorded. All missing data will be
explained.
Data collection is the responsibility of the principal in-
vestigator at each study site and is reviewed by the study
group.
Reasons for withdrawal will be documented carefully.
The investigator will attempt to contact the subjects at
least three times prior to designating them as lost to
follow-up. The investigator will document the date and
type of attempted communication. If a subject cannot be
reached during the visit window, a missed visit is re-
corded; after three consecutive missed visits, a subject is
considered lost to follow-up and a study exit form will
be completed on the electronic database. Any data on a
subject’s participation and procedures until the with-
drawal will be analyzed within the research.
All complications are recorded and monitored using a
specific eCRF. Data of all complications is later pub-
lished as part of the trial results.
Statistical methods
The primary endpoint will be the incidence of PSHs de-
tected by CT scan with 95% confidence intervals for all
groups at 1-year follow-up. Secondary outcomes are the
incidence of PSHs at 3- and 5-year follow-ups and the
development of quality of life during the follow-ups. The
analyses will be based on the intention-to-treat principle.
The primary endpoint and other categorical data will be
analyzed by the χ2 test or Fisher’s exact test. Analysis of
variance (ANOVA) will be used for continuous variables.
For repeatedly measured data, the linear mixed model
(LMM) will be used for continuous data and the gener-
alized linear mixed model (GLMM) will be used for cat-
egorical data. Multiple imputations of missing outcome
data will be used for sensitivity analyses. The SPSS stat-
istical programs (IBM Corp. 2016. IBM SPSS Statistics
for Windows, Version 24.0. Armonk, NY, USA) and SAS
(version 9.4, SAS Institute Inc., Cary, NC, USA) will be
used for the analyses.
Ethics and dissemination
Research ethics approval
This study follows the Declaration of Helsinki on med-
ical protocol and ethics. Each participating hospital ap-
plies for study permission at their unit. Central ethical
approval has been confirmed from the Ethical Commit-
tee at Oulu University Hospital (ref approval no. 324/
2018) and we will not begin recruiting at other centers
in the trial until local ethical approval has been
obtained.
Protocol amendments
Important protocol modifications are communicated
with the Oulu University Hospital Ethics Committee by
amendments. All modifications are also registered at
ClinicalTrials.gov.
Confidentiality
Patient confidentiality will be strictly maintained. Pa-
tients will be assigned a study ID, and all data will be
handled without name or personal Social Security num-
ber. Access to patient records is limited to the study
group and the investigator-delegated study coordinator.
Discussion
The aim of this study is to assess, in a randomized, mul-
ticenter setting, the safety and efficiency of specially
designed, funnel-shaped PVDF mesh (DynaMesh®-IPST,
FEG Textiltechnik GmbH, Aachen, Germany) in PSH
prevention compared with a control group without a
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mesh, all being operated on using mini-invasive laparo-
scopic/robotic methods. The hypothesis is that the high
incidence of up to 32% of PSHs detected on CT scans
after retromuscular sublay mesh [21] can be reduced
and further repair of PSHs can be prevented with the
use of a chimney-like tube in the PVDF mesh.
Research on specially designed PVDF mesh as prophy-
laxis is limited but promising with a PSH incidence rate
of 6.4% at 1-year-CT follow-up [23]. No RCTs using this
mesh exist so far. All previous case series [22–24] in-
cluded a small number of patients with no controls thus
providing inadequate evidence for efficiency and safety
for more routine use of this prophylactic mesh.
The focus of the current study is on the incidence of
PSHs at both short- and long-term follow-up.
PSHs are not only graded by European Hernia Soci-
ety Classification [25], but also the exact size and
content of hernias upon the Valsalva maneuver are
measured as well as the development of measure-
ments throughout the follow-up. Radiological risk fac-
tors for PSH development will be determined as part
of radiological follow-up. All symptoms caused by a
stoma itself or a PSH are recorded to analyze the
clinical significance of clinically or radiologically de-
tected PSHs. The quality of life is measured by both
RAND-36 and the colostomy impact score and re-
corded throughout the follow-up period as part of
defining the clinical significance of PSHs. The re-
operation rate and operations done for PSH are re-
corded in both groups.
This trial is designed as a single-blinded study for
safety reasons. In the case of serious complications de-
manding re-operation, it is crucial for decision-making
purposes to always have instant access to all technical
aspects of the surgery. Patients are blinded to the
method used during their hospital stay. Unfortunately, it
is impossible to blind patients beyond that time due to
direct access to the national medical database including
all medical records and hospital stays.
As current results from the use of the most evalu-
ated keyhole technique in PSH prevention are unsatis-
factory, more trials are needed to define the efficiency
and safety of other methods to prevent PSH. As pre-
vious research on the PVDF mesh used in this trial is
limited, there are clearly predefined safety limits of
PSH incidence and complications to determine when
to prematurely finish the trial as unethical to con-
tinue. For the same reason, the trial is designed to
compare the mesh group to control group without
any mesh to detect the objective efficiency and safety
of funnel-shaped PVDF mesh. Since there is a lack of
long-term results of PSH prevention, the sample size
is estimated to reach statistically significant results at
the long-term follow-up at 5 years.
Conclusions
The Chimney Trial aims to provide level-I evidence on
PSH prevention. The trial considers the economic as-
pects, effectiveness and safety profile with the scarcely
trialed PVDF mesh at both short- and long-term follow-
up.
Trial status
The trial started recruiting on 5 February 2019. The re-
cruitment is estimated to be complete by the end of
2021. The protocol date of protocol version 1 is 20
November 2018.
Abbreviations
APR: Abdominoperineal resection; CDC: Centers for Disease Control and
Prevention; CEA: Carcinoembryonic antigen; CRF: Case report form;
CT: Computed tomography; ERAS: Enhanced recovery after surgery;
GCP: Good Clinical Practice; LoS: Length of stay; PSH: Parastomal hernia;
PVDF : Polyvinylidene difluoride; SSI: Surgical-site infection; TNM: Tumor–
nodes–metastases; VAS: Visual analog scale
Authors’ contributions
The study was designed by TR, HW, JK, PO, EMU, and MN. EMU was the
major contributor in writing the manuscript. PO designed the statistical
methods of the study. All authors read and approved the final manuscript.
Funding
The materials used within this study are funded by the hospital district. The
Thelma Mäkikyrö Foundation has granted funding of €10,000 to the
Chimney Trial. The funding will be used to provide the research nurse for
the study and the authors’ time on research.
Availability of data and materials
The datasets generated and/or analyzed during the current study are not
publicly available due to Finnish laws on privacy protection but are available
from the corresponding author on reasonable request.
Ethics approval and consent to participate
The Ethical Committee at Oulu University Hospital has approved the
Chimney Trial and its consent to participate. Informed consent will be




The authors declare that they have no competing interests.
Author details
1Oulu University Hospital, PL 21, 90029 OYS, Finland. 2Päijät-Häme Central
Hospital, Keskussairaalankatu 7, 15850 Lahti, Finland. 3Västmanlands Hospital
Västerås, 721 89 Västerås, Sweden.
Received: 11 March 2019 Accepted: 28 September 2019
References
1. Miles WE. A method of performing abdomino-perineal excision for
carcinoma of the rectum and of the terminal portion of the pelvic colon
(Reprinted from The Lancet 1908). CA Cancer J Clin. 1971;21:361–4.
2. Heald RJ, Husband EM, Ryall RD. The mesorectum in rectal cancer surgery:
the clue to pelvic recurrence? Br J Surg. 1982;69:613–6.
3. Yeom S, Park I, Jung S, et al. Outcomes of patients with abdominoperineal
resection (APR) and low anterior resection (LAR) who had very low rectal
cancer. Medicine. 2017;96(43):e8249.
4. Sverrisson I, Nikberg M, Chabok A, Smedh K. Hartmann’s procedure in rectal
cancer: a population-based study of postoperative complications. Int J Color
Dis. 2015;30:181–6. https://doi.org/10.1007/s00384-014-2069-6.
Mäkäräinen-Uhlbäck et al. Trials          (2019) 20:652 Page 8 of 9
5. Jänes A, Cengiz Y, Israelsson LA. Preventing parastomal hernia with a
prosthetic mesh: a 5-year follow-up of a randomized study. World J Surg.
2009;33:118–21.
6. Ihnát P, Tulinský L, Jonszta T, Koscielnik P, Ihnát Rudinská L, Penka I.
Parastomal and incisional hernia following laparoscopic/open
abdominoperineal resection: is there a real difference? Surg Endosc. 2018;
21. https://doi.org/10.1007/s00464-018-6453-0.
7. Hansson BM. Parastomal hernia: treatment and prevention 2013: where do
we go from here? Color Dis. 2013;15:1467–70.
8. Vierimaa M, Klintrup K, Biancari F, Victorzon M, Carpelan-Holmström M,
Kössi J, Kellokumpu I, Rauvala E, Ohtonen P, Mäkelä J, Rautio T.
Prospective, randomized study on the use of a prosthetic mesh for
prevention of parastomal hernia of permanent colostomy. Dis Colon
Rectum. 2015;58:943–9.
9. Londono-Schimmer EE, Leong AP, Phillips RK. Lifetable analysis of stomal
complications following colostomy. Dis Colon Rectum. 1994;37:916–20.
10. Wik TA, Hjorthaug JO, Johannessen HO, Johnson E. Sigmoidostomy-related
parastomal hernia. Scand J Surg. 2011;100:186–9.
11. Antoniou SA, Agresta F, Garcia Alamino JM, Berger D, Berrevoet F,
Brandsma HT, et al. European Hernia Society guidelines on prevention
and treatment of parastomal hernias. Hernia. 2017. https://doi.org/10.
1007/s10029-017-1697-5.
12. Jänes A, Cengiz Y, Israelsson LA. Randomized clinical trial of the use of a
prosthetic mesh to prevent parastomal hernia. Br J Surg. 2004;91(3):280–2.
13. Lambrecht JR, Larsen SG, Reiertsen O, Vaktskjold A, Julsrud L, Flatmark K.
Prophylactic mesh at end-colostomy construction reduces parastomal
hernia rate: a randomized trial. Color Dis. 2015;17(10):O191–7.
14. Lopez-Cano M, Serra-Aracil X, Mora L, Sanchez-Garcia JL, Jimenez-Gomez
LM, Marti M, Vallribera F, Fraccalvieri D, Serracant A, Kreisler E, et al.
Preventing parastomal hernia using a modified Sugarbaker technique with
composite mesh during laparoscopic abdominoperineal resection: a
randomized controlled trial. Ann Surg. 2016;264(6):923–8.
15. Patel SV, Zhang L, Chadi SA, Wexner SD. Prophylactic mesh to prevent
parastomal hernia: a meta-analysis of randomized controlled studies. Tech
Coloproctol. 2017;21:5–13.
16. Brandsma HT, Hansson BM, Aufenacker TJ, van Geldere D, van Lammeren
FM, Mahabier C, Steenvoorde P, de Vries Reilingh TS, Wiezer RJ, de Wilt JH,
Bleichrodt RP, Rosman C. Prophylactic mesh placement to prevent
parastomal hernia, early results of a prospective multicentre randomized
trial. Hernia. 2016;20(4):535–41.
17. Cornille JB, Pathak S, Daniels IR, Smart NJ. Prophylactic mesh use during
primary stoma formation to prevent parastomal hernia. Hernia. 2017;99:2–11.
18. Cross A, Buchwald P, Frizelle F, et al. Meta-analysis of prophylactic mesh to
prevent parastomal hernia. Br J Surg. 2017;104:179–86.
19. Pianka F, Probst P, Keller AV. Prophylactic mesh placement for the
PREvention of paraSTOmal hernias: the PRESTO. Langenbeck's Arch Surg.
2017;402:949–55.
20. Chapman SJ, Wood B, Drake TM, et al. Systematic review and meta-analysis
of prophylactic mesh during primary stoma formation to prevent
parastomal hernia. Dis Colon Rectum. 2017;60:107–15. https://doi.org/10.
1097/DCR.0000000000000670.
21. Odensten C, Strigård K, Rutegård J, Dahlberg M, Ståhle U, Gunnarsson U, Näsvall P.
Use of prophylactic mesh when creating a colostomy does not prevent
parastomal hernia. Hernia. 2017. https://doi.org/10.1097/SLA.0000000000002542.
22. Berger D. Prevention of parastomal hernias by prophylactic use of a specially
designed intraperitoneal onlay mesh (DynaMesh®-IPST). Hernia. 2008;12:243–6.
23. Conde-Muino R, Diez JL, Martinez A, Huertas F, Inmaculada S, Palma P. Preventing
parastomal hernias with systematic intraperitoneal specifically designed mesh. BMC
Surg. 2017;17:41. https://doi.org/10.1186/s12893-017-0237-7.
24. Kohler G, Hofmann A, Lechner M, Mayer F, Wundsam H, Emmanuel K,
Fortelny RH. Prevention of parastomal hernias with 3D funnel meshes in
intraperitoneal onlay position by placement during initial stoma formation.
Hernia. https://doi.org/10.1007/s10029-015-1380-7.
25. Smietanski M, Szczepkowski M, Alexandre JA, et al. European Hernia Society
classification of parastomal hernias. Hernia. 2014;18:1–6.
26. CDC definition of surgical site infection. 2019. https://www.cdc.gov/nhsn/
pdfs/pscmanual/9pscssicurrent.pdf. Accessed 1 Jan 2019.
Publisher’s Note
Springer Nature remains neutral with regard to jurisdictional claims in
published maps and institutional affiliations.
Mäkäräinen-Uhlbäck et al. Trials          (2019) 20:652 Page 9 of 9
